News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Are Teva (TEVA)'s Best Days Behind It?



2/2/2017 6:29:54 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
After losing a patent challenge in U.S. District Court, it's become increasingly likely that Teva Pharmaceutical Industries' (NYSE:TEVA) top-selling Copaxone will face generic competition soon. Since Copaxone accounts for 16% of Teva Pharmaceutical's sales, and over 40% of its operating profit, investors are right to be nervous. Can Teva Pharmaceutical side-step the risk to Copaxone and reward investors?

Read at Motley Fool


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES